Smallpox Research Oversight Activities:WHO Advisory Committee on Variola Virus Research

Post Date

July 8th 2015

Application Due Date

September 10th 2015

Funding Opportunity Number

EP-IDS-15-003

CFDA Number(s)

93.019

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Number of Awards

1

Eligibility Categories

Other

WHO is the only eligible applicant; it is the only organization that is allowed by international agreements to address the issues outlined in this proposal. WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries, and monitoring and assessing health trends. In the 21st century, health is a shared responsibility, involving equitable access to essential care and collective defense against transnational threats. States Parties to the U.N. have agreed to international standards on reporting public health incidents of concern under IHR (2005). Additionally, a majority of States Parties have also agreed to specific work-frames for pathogens such as smallpox under the Biological Weapons Convention.

Funding

• Estimated Total Funding:

  $315000

• Award Range:

  $315000 - $315000

Grant Description

A natural re-emergence of smallpox is not deemed possible, but if it were to occur as a result of a terrorist or deliberate event, it would be a potentially devastating threat to public health worldwide and would constitute a public health emergency of international concern (PHEIC) under the International Health Regulations (IHR) (2005). A case of smallpox detected by a member state requires notification to WHO as soon as possible, and any confirmed smallpox case would generate an immediate global public health response. Since May 1999, when the 52nd World Health Assembly (WHA) resolved to postpone the destruction of the Variola virus to allow for this essential research (WHA 52.10), WHO has been charged with convening a group of experts to advise on the need for continuing such research, to review proposals for research involving viable Variola virus, to review the progress of such research, and to report to the WHA each year. The need to support the activities described in this project has not changed. The Variola virus research and stocks destruction are expected to be substantive agenda items at the 70th World Health Assembly in 2017.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  HHS - Office of the Secretary

• Agency Contact:

  Brenda Cox
  Grants Management Officer
  

• Agency Mailing Address:

  Business Email

• Agency Email Address:

  brenda.cox@hhs.gov

• Location:

  Assistant Secretary for Preparedness and Response